Claims
- 1. A compound of general formula (I):
- 2. A compound as claimed in claim 1, wherein X1, X2, X3, X4, and X5 are, respectively, >C—R′1 to >C—R′5, or alternatively not more than one of them is a nitrogen atom;
R1, R′1, R′2, R′3, R′4 and R′5 are identical or different, and each is: a hydrogen or halogen atom or an alkyl or alkyloxy radical, or is a methylene radical substituted with alkyloxy; R2 is carboxyl, alkyloxycarbonyl or —CONRaRb, wherein Ra is a hydrogen atom and Rb is a hydrogen atom or a hydroxyl radical; or R2 is hydroxymethyl, alkyl containing 1 or 2 carbon atoms substituted with carboxyl, or alkyloxycarbonyl; R3 is a radical alk-R°3 wherein
alk is an alkyl radical, and R°3 is hydrogen, cycloalkyl, cycloalkylthio, phenyl, phenoxy, phenylthio, phenylamino, heterocyclyloxy or heterocyclylthio, or alternatively R°3 is —CR′b=CR′c-R′a wherein R′a is phenyl, and wherein R′b and R′c are hydrogen; Y is a radical >CH—Re, wherein
Re is hydrogen, fluoro, or hydroxyl; n is an integer from 2 to 3; wherein any phenyl or heterocyclyl radical or portion is unsubtituted, or is substituted on the ring with from 1 to 4 halogens, and wherein any alkyl or acyl radical or portion, unless otherwise indicated, comprises from 1 to 10 carbon atoms in a straight or branched chain, and any cycloalkyl radical comprises from 3 to 6 carbon atoms; in any enantiomeric or diastereoisomeric form, in any syn or anti form, or any salt thereof, or mixture of any of the foregoing in any ratio.
- 3. 4-[3-(3-chloro-6-methoxyquinolin-4-yl)propyl]-1-[2-(thien-2-yl)thioethyl]piperidine-4-carboxylic acid, or any salt thereof.
- 4. 4-[3-(3-chloro-6-methoxyquinolin-4-yl)propyl]-1-[2-(3,5-difluorophenoxy)ethyl]piperidine-4-carboxylic acid, or any salt thereof.
- 5. 4-[3-(3-chloro-6-methoxyquinolin-4-yl)propyl]-1-(2-thiazol-2-thioethyl)piperidine-4-carboxylic acid, or any salt thereof.
- 6. 1-(2-cyclopentylthioethyl)-4-[3-(3-fluoro-6-methoxyquinolin-4-yl)propyl]piperidine-4-carboxylic acid, or any salt thereof.
- 7. 4-[3-(3-fluoro-6-methoxyquinolin-4-yl)propyl]-1-(3-phenylallyl)piperidine-4-carboxylic acid, or any salt thereof.
- 8. A process for preparing a compound as claimed in claim 1, comprising:
coupling a chain R3 as defined in claim 1 with a compound of general formula (II): 12wherein X1, X2, X3, X4, X5, R1, R2, Y and n are as defined in claim 1;optionally protecting R2 when R2 comprises a carboxyl or amino radical; optionally removing said protection from R2; optionally separating any enantiomeric or diastereoisomeric form, any syn or anti form, or any salt thereof; and optionally converting a product obtained into a salt thereof.
- 9. A process as claimed in claim 8, wherein said coupling of a chain R3 with a compound of general formula (II) occurs with a compound of general formula:
- 10. A process as claimed in claim 8, wherein
R3 is a radical -alk-R°3, wherein
alk is an alkyl radical, and R°3 is a radical —C≡C-Rd, wherein
Rd is phenyl, phenylalkyl, heterocyclyl or mono- or bicyclic aromatic heterocyclylalkyl; comprising: coupling an alkynyl halide, HC≡C-alk-X, wherein
alk is defined as above, and X is a halogen atom; and substituting the chain with a phenyl, phenylalkyl, heterocyclyl or heterocyclylalkyl radical.
- 11. A process as claimed in claim 9, wherein
R3 is a radical -alk-R°3, wherein
alk is an alkyl radical, and R°3 is a radical —C≡C-Rd, wherein
Rd is phenyl, phenylalkyl, heterocyclyl or mono- or bicyclic aromatic heterocyclylalkyl; comprising: coupling an alkynyl halide, HC≡C-alk-X, wherein
alk is defined as above, and X is a halogen atom; and substituting the chain with a phenyl, phenylalkyl, heterocyclyl or heterocyclylalkyl radical.
- 12. A process as claimed in claim 8, wherein:
R3 is a radical -alk-R°3, wherein alk is an alkyl radical, and R°3 is a phenoxy, phenylthio, phenylamino, heterocyclyloxy, heterocyclylthio or heterocyclylamino radical in which the heterocyclyl portion is aromatic; comprising constructing the chain stepwise by: condensing a chain HO-alk-X wherein
X is a halogen atom; obtaining a hydroxyalkyl chain; converting the hydroxyalkyl chain into a haloalkyl, methanesulfonylalkyl, or p-toluenesulfonylalkyl chain by known methods; and reacting the chain in basic medium with an aromatic derivative of structure Ar-ZH, wherein Ar is a phenyl or aromatic heterocyclyl radical, and Z is a sulfur, oxygen, or nitrogen atom.
- 13. A process as claimed in claim 9, wherein:
R3 is a radical -alk-R°3, wherein
alk is an alkyl radical, and R°3 is a phenoxy, phenylthio, phenylamino, heterocyclyloxy, heterocyclylthio or heterocyclylamino radical in which the heterocyclyl portion is aromatic, comprising constructing the chain stepwise by: condensing a chain HO-alk-X wherein
X is a halogen atom; obtaining a hydroxyalkyl chain; converting the hydroxyalkyl chain into a haloalkyl, methanesulfonylalkyl, or p-toluenesulfonylalkyl chain by known methods; and reacting the chain in basic medium with an aromatic derivative of structure Ar-ZH, wherein Ar is a phenyl or aromatic heterocyclyl radical, and Z is a sulfur, oxygen, or nitrogen atom.
- 14. A pharmaceutical composition, comprising at least one compound according to claim 1, alone, or in combination with one or more pharmaceutically acceptable adjuvants or diluents.
- 15. A pharmaceutical composition, comprising at least one compound according to claim 3, alone, or in combination with one or more pharmaceutically acceptable adjuvants or diluents.
- 16. A pharmaceutical composition, comprising at least one compound according to claim 4, alone, or in combination with one or more pharmaceutically acceptable adjuvants or diluents.
- 17. A pharmaceutical composition, comprising at least one compound according to claim 5, alone, or in combination with one or more pharmaceutically acceptable adjuvants or diluents.
- 18. A pharmaceutical composition, comprising at least one compound according to claim 6, alone, or in combination with one or more pharmaceutically acceptable adjuvants or diluents.
- 19. A pharmaceutical composition, comprising at least one compound according to claim 7, alone, or in combination with one or more pharmaceutically acceptable adjuvants or diluents.
Priority Claims (1)
Number |
Date |
Country |
Kind |
FR 00 14738 |
Nov 2000 |
FR |
|
Parent Case Info
[0001] The present application claims priority of U.S. Provisional Application No. 60/255,145, filed Dec. 14, 2000, and of French Patent Application No. FR 00 14738, filed Nov. 15, 2000, all of which are specifically incorporated by reference herein.
Divisions (1)
|
Number |
Date |
Country |
Parent |
09987386 |
Nov 2001 |
US |
Child |
10607220 |
Jun 2003 |
US |